IceCure Medical Successfully Completes 5-Year Patient Follow Up in ICESECRET Kidney Cancer Cryoablation Study: Final Analysis Expected in Second Quarter of 2026
IceCure Medical Ltd. - Ordinary Shares (ICCM)
Company Research
Source: PR Newswire
Previously released interim data from 111 patients demonstrated ProSense® is safe and effective in destruction of kidney tumors with 88.7% recurrence-free rateIncidence of kidney cancer is growing worldwide, with an estimated 400,000 new cases globally; over 80,000 of which are in the U.S. alone highlighting a growing unmet needProSense® is approved for benign and malignant kidney tumors in the U.S., Europe, and numerous other countriesCAESAREA, Israel, Feb. 23, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced the completion of its last patients' five-year follow up evaluation in its ICESECRET clinical trial of ProSense® for the treatment of small renal masses ("SRMs") in kidney cancer patients. ICESECRET, a prospective, multicenter, single-arm clinical trial, was performed at Bnai Zio
Show less
Read more
Impact Snapshot
Event Time:
ICCM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ICCM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ICCM alerts
High impacting IceCure Medical Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
ICCM
News
- IceCure Participates in Society of Breast Imaging Symposium 2026 as U.S. ProSense® Revenue Increases by 30%+ in First Quarter of 2026 Compared to First Quarter of 2025PR Newswire
- IceCure Reports Positive 5-Year Top-Line Results from ICESECRET Kidney Cancer Cryoablation Study: 89.4% and 83.9% Recurrence-Free RatesPR Newswire
- IceCure Appoints Meir Peleg as Chief Financial OfficerPR Newswire
- Icecure Medical Ltd (ICCM) Q4 2025 Earnings Call Highlights: Record Sales and Strategic U.S. ... [Yahoo! Finance]Yahoo! Finance
- IceCure Medical (ICCM) Q4 2025 Earnings Transcript [Yahoo! Finance]Yahoo! Finance
ICCM
Earnings
- 3/17/26 - Beat
ICCM
Sec Filings
- 4/22/26 - Form 6-K
- 4/21/26 - Form 6-K
- 4/13/26 - Form EFFECT
- ICCM's page on the SEC website